

CUMBERLAND PHARMACEUTICALS INC

Reported by JACOBS JOEY A

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 04/07/17 for the Period Ending 04/07/17

Address 2525 WEST END AVENUE

SUITE 950

NASHVILLE,, TN 37203

Telephone 615-255-0068

CIK 0001087294

Symbol CPIX

SIC Code 2834 - Pharmaceutical Preparations

Industry Pharmaceuticals

Sector Healthcare





[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
JACOBS JOEY A					CUMBERLAND PHARMACEUTICALS INC [CPIX]							X Director	X Director 10% Owner				
(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)						Officer (giv	ve title below	v)O	ther (specify	below)			
2525 WEST END AVENUE, SUITE 950					4/7/2017												
	(Str	eet)			4. If Amendment, Date Original Filed (MM/DD/YYYY)						(a) 6. Individual	6. Individual or Joint/Group Filing (Check Applicable Line)					
NASHVILL (C	*		ip)									X Form filed by		orting Person One Reporting P	'erson		
			Table									Seneficially Own					
1.Title of Security (Instr. 3) 2. Trans. D						3. Trans. Code (Instr. 8)		or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
							Code	V	Amount	(A) or (D)	Price					(Instr. 4)	
Common Stock 4/7/2017						A		1000 (1)	A	\$6.45		57000					
	Tab	ole II - Dei	rivative	Securiti	es Be	eneficiall	y Owned (e.g.	, puts,	calls, w	arrant	s, options, conve	rtible sec	eurities)			
1. Title of Derivate Security (Instr. 3)	ccurity Conversion or Exercise Price of Derivative Execution Date, if any		on (Instr		Code 5. Number of Derivative Securiti Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					Securit Derivat	and Amount of ies Underlying ive Security 3 and 4)		derivative Securities Beneficially Owned	Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Security			Co	de	V (A)	(D)	Date	e Ercisable I	Expiration Date		Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)		

Explanation of Responses:

(1) Restricted stock award will vest 100% on March 17, 2018.

Reporting Owners

Panorting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
JACOBS JOEY A 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203	X						

Signatures

Joey A. Jacobs by /s/ Michael Bonner as attorney-in-fact

Signature of Reporting Person

4/7/201

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.